+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Central Nervous System Therapeutics Market by Disorders, Drug Type, Route of Administration, End-Users - Global Forecast 2025-2030- Product Image
Central Nervous System Therapeutics Market by Disorders, Drug Type, Route of Administration, End-Users - Global Forecast 2025-2030- Product Image
Sale

Central Nervous System Therapeutics Market by Disorders, Drug Type, Route of Administration, End-Users - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 199 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5665844
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Central Nervous System Therapeutics Market grew from USD 133.83 billion in 2023 to USD 143.11 billion in 2024. It is expected to continue growing at a CAGR of 7.24%, reaching USD 218.45 billion by 2030.

Central Nervous System (CNS) therapeutics encompass a range of treatment modalities aimed at disorders affecting the brain and spine, such as Alzheimer's, Parkinson's, epilepsy, and multiple sclerosis. The necessity for CNS therapeutics is driven by the growing prevalence of these disorders, an aging global population, and advancements in biomedical research that continuously uncover new pathways and drug targets. Applications span pharmaceuticals, biologics, and novel delivery systems, with end-users including hospitals, specialized clinics, and research institutions. Key growth factors influencing the CNS therapeutics market include heightened investments in R&D, regulatory support encouraging orphan drug status for novel CNS drugs, and the increasing demand for personalized medicine. Furthermore, groundbreaking technologies like AI and machine learning are now being adopted to enhance drug discovery and personalized treatment protocols. Current opportunities lie in leveraging breakthroughs in gene therapy, CRISPR-based gene editing, and neurotechnology, which promise to offer effective solutions for traditionally treatment-resistant CNS diseases. However, the market faces limitations such as high R&D costs, long development timelines, and stringent regulatory hurdles. Additionally, the complexity of CNS disorders presents significant challenges in both diagnosis and treatment efficacy, necessitating comprehensive approaches combining pharmacological and non-pharmacological interventions. Innovative areas offering business growth include the development of biomarker-based diagnostics and targeted drug delivery systems, as well as non-invasive neurostimulation techniques. Insights suggest that the market is dynamic, with a competitive landscape characterized by both established pharmaceutical giants and burgeoning biotech startups. To harness maximum growth potential, businesses should focus on strategic partnerships, open innovation funding models, and close collaboration with academic institutions. Emphasizing patient-centric care models and digital health integration will also be vital in overcoming current market barriers and ensuring long-term growth.

Understanding Market Dynamics in the Central Nervous System Therapeutics Market

The Central Nervous System Therapeutics Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Growing elderly population and the prevalence of neurodegenerative disorders
    • Implementation of government initiatives & funding for research on neurological disorders
  • Market Restraints
    • Rising cases of product recall associated with the CNS drugs
  • Market Opportunities
    • Investment in gene-editing technologies and stem cell research for neurodegenerative diseases
    • Potential utilization of nanomaterials for innovative drug formulation
  • Market Challenges
    • Complexities of CNS disorders coupled with difficulty in crossing the blood-brain barrier

Exploring Porter’s Five Forces for the Central Nervous System Therapeutics Market

Porter’s Five Forces framework further strengthens the insights of the Central Nervous System Therapeutics Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Central Nervous System Therapeutics Market

External macro-environmental factors deeply influence the performance of the Central Nervous System Therapeutics Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Central Nervous System Therapeutics Market

The Central Nervous System Therapeutics Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Central Nervous System Therapeutics Market

The Central Nervous System Therapeutics Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Central Nervous System Therapeutics Market

The Central Nervous System Therapeutics Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Central Nervous System Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AC Immune SA, Acadia Pharmaceuticals Inc., Acorda Therapeutics, Inc., Alkermes PLC, Amgen Inc., AstraZeneca PLC, Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, Cassava Sciences, Inc., Cipla Limited, CNS Pharmaceuticals, Inc., Denali Therapeutics Inc., Eisai Co. Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, H. Lundbeck A/S, Intra-Cellular Therapies, Inc., Ipsen S.A., Johnson & Johnson Services, Inc., Lupin Limited, MapLight Therapeutics, Inc., Merck KGaA, Minerva Neurosciences, Inc., Neuraxpharm, Novartis AG, Novo Nordisk A/S, Otsuka Holdings Co Ltd, Pfizer Inc., Polpharma Biologics S.A., Rapport Therapeutics, Inc., Sage Therapeutics, Inc., Sanofi S.A., Sun Pharmaceutical Industries Limited, Supernus Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, TauRx Pharmaceuticals Ltd, Teva Pharmaceutical Industries Ltd., and UCB S.A..

Market Segmentation & Coverage

This research report categorizes the Central Nervous System Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Disorders
    • Epileptic Disorders
      • Epilepsy
      • Seizure Disorders
    • Neurodegenerative Diseases
      • Alzheimer’s Disease
      • Amyotrophic Lateral Sclerosis
      • Multiple Sclerosis
      • Parkinson’s Disease
    • Pain Management
      • Acute Pain
      • Chronic Pain
      • Neuropathic Pain
    • Psychiatric Disorders
      • Anxiety Disorders
      • Bipolar Disorder
      • Depression
      • Schizophrenia
  • Drug Type
    • Biologics
      • Gene Therapies
      • Monoclonal Antibodies
      • Peptides
      • Stem Cell Therapies
    • Small Molecules
  • Route of Administration
    • Injectable
      • Intramuscular
      • Intravenous
      • Subcutaneous
    • Oral
    • Transdermal
  • End-Users
    • Hospitals
    • Research Institutes
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing elderly population and the prevalence of neurodegenerative disorders
5.1.1.2. Implementation of government initiatives & funding for research on neurological disorders
5.1.2. Restraints
5.1.2.1. Rising cases of product recall associated with the CNS drugs
5.1.3. Opportunities
5.1.3.1. Investment in gene-editing technologies and stem cell research for neurodegenerative diseases
5.1.3.2. Potential utilization of nanomaterials for innovative drug formulation
5.1.4. Challenges
5.1.4.1. Complexities of CNS disorders coupled with difficulty in crossing the blood-brain barrier
5.2. Market Segmentation Analysis
5.2.1. Disorders: Increasing epileptic disorder prevalence and significant unmet medical needs
5.2.2. Drug Type: Innovative biologics for particular and potent treatments
5.2.3. Route of Administration: High preference for injectable routes owing to their long-acting formulations
5.2.4. End-Users: Significant demand for CNS therapeutics in hospitals for immediate interventions
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Central Nervous System Therapeutics Market, by Disorders
6.1. Introduction
6.2. Epileptic Disorders
6.2.1. Epilepsy
6.2.2. Seizure Disorders
6.3. Neurodegenerative Diseases
6.3.1. Alzheimer’s Disease
6.3.2. Amyotrophic Lateral Sclerosis
6.3.3. Multiple Sclerosis
6.3.4. Parkinson’s Disease
6.4. Pain Management
6.4.1. Acute Pain
6.4.2. Chronic Pain
6.4.3. Neuropathic Pain
6.5. Psychiatric Disorders
6.5.1. Anxiety Disorders
6.5.2. Bipolar Disorder
6.5.3. Depression
6.5.4. Schizophrenia
7. Central Nervous System Therapeutics Market, by Drug Type
7.1. Introduction
7.2. Biologics
7.2.1. Gene Therapies
7.2.2. Monoclonal Antibodies
7.2.3. Peptides
7.2.4. Stem Cell Therapies
7.3. Small Molecules
8. Central Nervous System Therapeutics Market, by Route of Administration
8.1. Introduction
8.2. Injectable
8.2.1. Intramuscular
8.2.2. Intravenous
8.2.3. Subcutaneous
8.3. Oral
8.4. Transdermal
9. Central Nervous System Therapeutics Market, by End-Users
9.1. Introduction
9.2. Hospitals
9.3. Research Institutes
9.4. Specialty Clinics
10. Americas Central Nervous System Therapeutics Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Central Nervous System Therapeutics Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Central Nervous System Therapeutics Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. Amneal Pharmaceuticals receives FDA approval for CREXONT to enhance Parkinson’s therapy
13.3.2. Asceneuron secures USD 100M to advance ASN51 for neurodegenerative diseases
13.3.3. Eli Lilly's Kisunla receives FDA approval for early Alzheimer's treatment
13.3.4. Roche and Ascidian Therapeutics join forces to develop innovative RNA therapies for neurological diseases
13.3.5. Voyager Therapeutics initiates Phase 1a trial of VY-TAU01 for Alzheimer's
13.3.6. Supernus Pharmaceuticals receives FDA Complete Response Letter for SPN-830
13.3.7. Sanofi India partners with Cipla to enhance distribution and promotion of CNS therapeutics to improve patient outcomes
13.3.8. Engrail Therapeutics secures USD 157M Series B funding to advance non-addictive CNS therapies and expand strategic partnerships
13.3.9. Myrobalan Therapeutics secures USD 24 million in Series A funding to advance CNS treatments
13.3.10. AbbVie launches Produodopa, a groundbreaking 24-hour subcutaneous infusion therapy for advanced Parkinson's in the EU
13.3.11. 4D Molecular Therapeutics and Arbor Biotechnologies partner to advance innovative genetic therapies for CNS disorders
13.3.12. MapLight Therapeutics secures USD 225 million Series C funding to advance CNS therapies
13.3.13. Pharmanovia expands neurology portfolio by acquiring 11 CNS brands from Sanofi
13.3.14. Novartis strengthens neuroscience pipeline with USD 500M acquisition of siRNA-focused DTx Pharma
13.3.15. Neurocrine Biosciences collaborates with Voyager Therapeutics on USD 175M gene therapy deal
13.4. Strategy Analysis & Recommendation
13.4.1. F. Hoffmann-La Roche AG
13.4.2. Bristol-Myers Squibb Company
13.4.3. Lupin Limited
13.4.4. AbbVie Inc.
List of Figures
FIGURE 1. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2023 VS 2030 (%)
FIGURE 7. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
FIGURE 13. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET DYNAMICS
TABLE 7. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SEIZURE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ALZHEIMER’S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PARKINSON’S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANXIETY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIPOLAR DISORDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEPRESSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SCHIZOPHRENIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STEM CELL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 60. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 80. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
TABLE 81. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 82. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 83. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 84. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 85. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 86. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 87. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 89. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 90. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
TABLE 91. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 92. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 93. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 94. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 95. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 96. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 97. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 99. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 111. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
TABLE 112. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 113. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 114. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 115. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 116. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 117. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 118. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 120. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 121. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 122. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
TABLE 123. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 124. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 125. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 126. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 127. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 128. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 129. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 131. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 132. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
TABLE 133. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 134. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 135. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 136. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 137. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 138. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 139. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 141. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 142. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
TABLE 143. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 144. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 145. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 146. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 147. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 148. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 149. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 150. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 151. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 152. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
TABLE 153. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 154. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 155. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 156. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 157. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 158. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 159. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 161. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 162. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
TABLE 163. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 164. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 165. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 166. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 167. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 168. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 169. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 171. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 172. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
TABLE 173. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 174. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 175. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 176. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 177. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 178. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 179. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 181. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 182. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
TABLE 183. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 184. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 185. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 186. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 187. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 188. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 189. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 191. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 192. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
TABLE 193. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 194. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 195. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 196. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 197. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 198. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 199. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 200. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 201. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 202. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
TABLE 203. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 204. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 205. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 206. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 207. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 208. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 209. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 211. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 212. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
TABLE 213. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 214. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 215. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 216. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 217. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 218. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 219. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 221. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 222. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
TABLE 223. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 224. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 225. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 226. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 227. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 228. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 229. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 231. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 232. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
TABLE 233. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 234. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 235. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 236. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 237. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 238. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 239. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 240. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 241. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 253. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
TABLE 254. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 255. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 256. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 257. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 258. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 259. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 260. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 261. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 262. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 263. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
TABLE 264. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 265. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 266. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 267. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 268. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 269. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 270. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 271. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 272. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 273. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
TABLE 274. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 275. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 276. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 277. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 278. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 279. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 280. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 281. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 282. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 283. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
TABLE 284. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 285. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
TABLE 286. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 287. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 288. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 289. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD

Companies Mentioned

The leading players in the Central Nervous System Therapeutics market, which are profiled in this report, include:
  • AbbVie Inc.
  • AC Immune SA
  • Acadia Pharmaceuticals Inc.
  • Acorda Therapeutics, Inc.
  • Alkermes PLC
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • C.H. Boehringer Sohn AG & Co. KG
  • Cassava Sciences, Inc.
  • Cipla Limited
  • CNS Pharmaceuticals, Inc.
  • Denali Therapeutics Inc.
  • Eisai Co. Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Intra-Cellular Therapies, Inc.
  • Ipsen S.A.
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • MapLight Therapeutics, Inc.
  • Merck KGaA
  • Minerva Neurosciences, Inc.
  • Neuraxpharm
  • Novartis AG
  • Novo Nordisk A/S
  • Otsuka Holdings Co Ltd
  • Pfizer Inc.
  • Polpharma Biologics S.A.
  • Rapport Therapeutics, Inc.
  • Sage Therapeutics, Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Limited
  • Supernus Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • TauRx Pharmaceuticals Ltd
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages199
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 143.11 Billion
Forecasted Market Value ( USD ) by 2030 $ 218.45 Billion
Compound Annual Growth Rate7.2%
Regions CoveredGlobal
No. of Companies Mentioned42

Related Topics

Related Reports

Central Nervous System Drugs Market by Drug Classes, Diseases, Drug Type, Distribution Channel - Global Forecast 2025-2030 - Product Image

Central Nervous System Drugs Market by Drug Classes, Diseases, Drug Type, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Central Nervous System Therapeutics Market Size, Share & Trends Analysis Report by Disease, Drug Class (Anticonvulsants, CNS Stimulants), Distribution Channel, Region, and Segment Forecasts, 2025-2030 - Product Image

Central Nervous System Therapeutics Market Size, Share & Trends Analysis Report by Disease, Drug Class (Anticonvulsants, CNS Stimulants), Distribution Channel, Region, and Segment Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Central Nervous System Therapeutics Market Report and Forecast 2024-2032 - Product Image

Central Nervous System Therapeutics Market Report and Forecast 2024-2032

  • Report
  • 160 Pages
  • Global
From
Central Nervous System Therapeutic Market - Product Image

Central Nervous System Therapeutic Market

  • Report
  • 200 Pages
  • Global
From
Central Nervous System Therapeutics Market Report by Disease, Application, and Region 2024-2032 - Product Image

Central Nervous System Therapeutics Market Report by Disease, Application, and Region 2024-2032

  • Report
  • 137 Pages
  • Global
From

About the Central Nervous System Drugs Market

The Central Nervous System Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs that target the central nervous system. These drugs are used to treat a variety of conditions, including neurological disorders, mental health issues, and pain management. The market is composed of a variety of companies, ranging from large multinationals to small start-ups. The Central Nervous System Drugs market is highly competitive, with companies competing to develop the most effective and safe treatments. Companies in the market are constantly researching and developing new drugs, as well as improving existing treatments. Many of these companies are also involved in clinical trials to test the safety and efficacy of their products. Some of the major companies in the Central Nervous System Drugs market include Pfizer, GlaxoSmithKline, Merck, Novartis, and Johnson & Johnson. These companies are involved in the development and production of a wide range of CNS drugs, including antidepressants, antipsychotics, and anticonvulsants. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.